ATE450604T1 - Gsk3-polypeptide - Google Patents

Gsk3-polypeptide

Info

Publication number
ATE450604T1
ATE450604T1 AT07022387T AT07022387T ATE450604T1 AT E450604 T1 ATE450604 T1 AT E450604T1 AT 07022387 T AT07022387 T AT 07022387T AT 07022387 T AT07022387 T AT 07022387T AT E450604 T1 ATE450604 T1 AT E450604T1
Authority
AT
Austria
Prior art keywords
gsk3
polypeptides
amino acid
substituted amino
type
Prior art date
Application number
AT07022387T
Other languages
English (en)
Inventor
Stephen D Harrison
John A Hall
Maria Calderon-Cacia
Ziyang Zhong
Eric Y Fang
Doris G Coit
Steven H Nguyen
Angelica Medina-Selby
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE450604T1 publication Critical patent/ATE450604T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
AT07022387T 2000-07-27 2001-07-25 Gsk3-polypeptide ATE450604T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22124200P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
ATE450604T1 true ATE450604T1 (de) 2009-12-15

Family

ID=22826991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07022387T ATE450604T1 (de) 2000-07-27 2001-07-25 Gsk3-polypeptide

Country Status (10)

Country Link
US (6) US6465231B2 (de)
EP (2) EP1914305B1 (de)
JP (1) JP2004504838A (de)
CN (1) CN1276974C (de)
AT (1) ATE450604T1 (de)
AU (1) AU2001280812A1 (de)
DE (2) DE60140707D1 (de)
ES (1) ES2295191T3 (de)
PT (2) PT1319064E (de)
WO (1) WO2002010357A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292906B2 (en) * 2000-09-19 2007-08-16 Novartis Vaccines And Diagnostics, Inc. Characterization of the GSK-3beta protein and methods of use thereof
WO2003068932A2 (en) 2002-02-11 2003-08-21 Chiron Corporation Method for crystallizing human gsk3 and novel crystal structure thereof
WO2005083111A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (gsk3a)
US20060127388A1 (en) * 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
EP1845094A4 (de) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp Verfahren zur tumorsuppression und bewertung von antikrebsmitteln basierend auf einer gsk3-beta-hemmenden wirkung
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
NZ564285A (en) * 2005-06-20 2010-03-26 Decode Genetics Ehf Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
CA2618613A1 (en) * 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
US20160135446A1 (en) 2013-06-13 2016-05-19 Biomatrica, Inc. Cell stabilization
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN106572650B (zh) 2014-06-10 2021-08-31 生物马特里卡公司 在环境温度下稳定凝血细胞
EP4242628A3 (de) 2015-12-08 2023-11-08 Biomatrica, INC. Verringerung der erythrozytensedimentationsrate
CN117384983B (zh) * 2023-12-07 2024-02-23 中国中医科学院中药研究所 一种GSK-3α抑制剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591872A (en) * 1993-08-09 1997-01-07 The University Of Iowa Research Foundation Autoinducer molecule
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5693496A (en) * 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP1082430A1 (de) * 1998-05-28 2001-03-14 ZymoGenetics, Inc. Kunitzdomäne-polypeptide
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6057218A (en) * 1999-05-07 2000-05-02 Vanguard International Semiconductor Corporation Method for simultaneously manufacturing poly gate and polycide gate

Also Published As

Publication number Publication date
EP1914305A1 (de) 2008-04-23
US20020082408A1 (en) 2002-06-27
PT1914305E (pt) 2010-01-29
US20030077798A1 (en) 2003-04-24
WO2002010357A3 (en) 2003-04-03
AU2001280812A1 (en) 2002-02-13
PT1319064E (pt) 2008-02-29
EP1319064B1 (de) 2007-11-21
DE60131550D1 (en) 2008-01-03
DE60131550T2 (de) 2008-10-23
US20080182313A1 (en) 2008-07-31
US6716624B2 (en) 2004-04-06
US20050048511A1 (en) 2005-03-03
US20070249004A1 (en) 2007-10-25
ES2295191T3 (es) 2008-04-16
CN1276974C (zh) 2006-09-27
DE60140707D1 (de) 2010-01-14
US7135321B2 (en) 2006-11-14
CN1468302A (zh) 2004-01-14
US6465231B2 (en) 2002-10-15
US7807430B2 (en) 2010-10-05
EP1914305B1 (de) 2009-12-02
EP1319064A2 (de) 2003-06-18
JP2004504838A (ja) 2004-02-19
US7195886B2 (en) 2007-03-27
US20060088932A1 (en) 2006-04-27
US7361484B2 (en) 2008-04-22
WO2002010357A2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
ATE450604T1 (de) Gsk3-polypeptide
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
BR0316502A (pt) Compostos quìmicos
NO931889L (no) Protease og beslektede DNA-forbindelser
DE69422726D1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
DE69429527T2 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE244717T1 (de) Inhibitoren des impdh-enzyms
BR9806752A (pt) Ftalazinonas.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
WO2003039454A3 (en) Beta-secretase inhibitors and methods of use
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200400699A1 (ru) 3,4-дизамещенные, 3,5-дизамещенные и 3,4,5-замещенные пиперидины и пиперазины
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
ATE348611T1 (de) Derivate des phenoxy-n-'4-(isothiazolidin-1,1- dioxid-2yl)pheny)-valerian-säureamids und andere verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen und tumoren
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60111849D1 (de) Purin-2,6-dione als inhibitoren des enzyms dipeptidyl-peptidase iv (dpp-iv)
DE69809785D1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ATE391915T1 (de) Verwendung des proteins grf-1 zur auswahl von molekülen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1914305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee